Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Otorhinolaryngology

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 130 articles: HTML format

Single Articles

July 2025
1. LIU ZQ, Zang SB, OuYang PY, Jing BZ, et al
   Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy.
   Radiother Oncol. 2025 Jul 1:111010. doi: 10.1016/j.radonc.2025.111010.
   PubMed     Abstract available
   
   
   
2. YANG F, Wang D, Su Y, Tang J, et al
   The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.
   Radiother Oncol. 2025 Jul 1:111012. doi: 10.1016/j.radonc.2025.111012.
   PubMed     Abstract available
   
   
   June 2025
3. POPULAIRE P, Defraene G, Liu Y, Titt U, et al
   Dose to the left ventricle is associated to the risk of acute cardiac toxicity in patients with esophageal cancer undergoing trimodality treatment.
   Radiother Oncol. 2025;209:111002.
   PubMed     Abstract available
   
   
   
4. ZHENG Q, Yu X, Pan W, Ai Y, et al
   Deep learning dosiomics in grade 4 radiation-induced lymphopenia prediction in radiotherapy for esophageal cancer: a multi-center study.
   Radiother Oncol. 2025;209:110995.
   PubMed     Abstract available
   
   
   
5. LI Y, Liang J, Fu G, Pan J, et al
   Non-linear early rapid hippocampal atrophy and associated microstructural injury in patients with nasopharyngeal carcinoma after radiotherapy: Implications for hippocampal protection.
   Radiother Oncol. 2025;209:110997.
   PubMed     Abstract available
   
   
   
6. LI J, He HG, Guan C, Ding Y, et al
   Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.
   Radiother Oncol. 2025;209:110993.
   PubMed     Abstract available
   
   
   
7. MOHARRAMI M, Watson E, Huang SH, Madathil S, et al
   Defining the optimal radiation thresholds for Stratifying jaw osteoradionecrosis risk in head and neck cancer.
   Radiother Oncol. 2025;209:110996.
   PubMed     Abstract available
   
   
   
8. BACHMANN N, Ahmadsei M, Hurlimann M, Gabrys HS, et al
   Cone-beam computed tomography-based online adaptive radiotherapy of esophageal cancer in the neoadjuvant setting: Dosimetric analysis, toxicity and treatment response.
   Radiother Oncol. 2025;209:110981.
   PubMed     Abstract available
   
   
   
9. NGAN TH, Yeh SH, Tien HJ, Hsu CX, et al
   Bao Yuan Gao vs. Calendula cream for radiotherapy-induced skin toxicity in head and neck cancer: A randomized controlled trial.
   Radiother Oncol. 2025;209:110976.
   PubMed     Abstract available
   
   
   
10. NIELSEN AM, Laursen MRT, Rechner LA, Krog SM, et al
    Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial.
    Radiother Oncol. 2025;207:110906.
    PubMed     Abstract available
    
    
    
11. YARLAGADDA S, Rohe RM, McNeill V, Nemec JR, et al
    Tubarial gland sparing for oropharyngeal cancer: Feasibility with intensity modulated proton therapy & intensity modulated radiation therapy.
    Radiother Oncol. 2025;207:110882.
    PubMed     Abstract available
    
    
    
12. GAWRYSZUK A, van der Laan HP, Vergeer MR, Veening M, et al
    Improved NTCP model for late radiation-induced aspiration based on dose delivered to specific aspiration-related OARs.
    Radiother Oncol. 2025;207:110871.
    PubMed     Abstract available
    
    
    
13. HUGHES A, Johnny C, Huang SH, Su J, et al
    The prognostic and predictive value of pre-treatment hematologic markers for oropharyngeal carcinoma stratified by HPV status and treated with definitive (chemo) radiation.
    Radiother Oncol. 2025;207:110851.
    PubMed     Abstract available
    
    
    
14. MA B, Guo J, Dijk LVV, Langendijk JA, et al
    PET and CT based DenseNet outperforms advanced deep learning models for outcome prediction of oropharyngeal cancer.
    Radiother Oncol. 2025;207:110852.
    PubMed     Abstract available
    
    
    May 2025
15. XIANG Z, Yu X, Lin S, Wang D, et al
    Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.
    Radiother Oncol. 2025 May 22:110951. doi: 10.1016/j.radonc.2025.110951.
    PubMed     Abstract available
    
    
    
16. YI X, Yu X, Li C, Li J, et al
    Deep learning Radiopathomics based on pretreatment MRI and whole slide images for predicting overall survival in locally advanced nasopharyngeal carcinoma.
    Radiother Oncol. 2025;209:110949.
    PubMed     Abstract available
    
    
    
17. DING J, Yin X, Lin Y, Liao X, et al
    Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis.
    Radiother Oncol. 2025;208:110943.
    PubMed     Abstract available
    
    
    
18. CHEN SY, Duan XT, Xie RL, Han YQ, et al
    Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 May 2:110913. doi: 10.1016/j.radonc.2025.110913.
    PubMed     Abstract available
    
    
    
19. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
    'iCycle-pBAO': Automated patient-specific beam-angle selection in proton therapy applied to oropharyngeal cancer.
    Radiother Oncol. 2025;206:110799.
    PubMed     Abstract available
    
    
    
20. CARSUZAA F, Favier V, Seguin L, Turri-Zanoni M, et al
    Consensus for a postoperative atlas of sinonasal substructures from a modified Delphi study to guide radiotherapy in sinonasal malignancies.
    Radiother Oncol. 2025;206:110784.
    PubMed     Abstract available
    
    
    April 2025
21. YAN Y, Zhao F
    Response to the commentary on "Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning" by Mohammad Zahid, and Heiko Enderling.
    Radiother Oncol. 2025;208:110903.
    PubMed    
    
    
    
22. ERIKSEN JG, Maare C, Johansen J, Primdahl H, et al
    DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
    Radiother Oncol. 2025 Apr 19:110899. doi: 10.1016/j.radonc.2025.110899.
    PubMed     Abstract available
    
    
    
23. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers FJP, et al
    Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma.
    Radiother Oncol. 2025 Apr 17:110900. doi: 10.1016/j.radonc.2025.110900.
    PubMed     Abstract available
    
    
    
24. WANG Z, Li L, Wu Y, Liu Z, et al
    Development and validation of Prediction models for radiation-induced hypoglossal neuropathy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Apr 8:110887. doi: 10.1016/j.radonc.2025.110887.
    PubMed     Abstract available
    
    
    
25. HIRAOKA S, Hirashima H, Nakamura M, Tanaka F, et al
    Integration test of biaxially rotational dynamic-radiation therapy for nasopharyngeal carcinoma: Efficacy evaluation and dosimetric analysis.
    Radiother Oncol. 2025;207:110879.
    PubMed     Abstract available
    
    
    
26. YANG F, Peng W, Wei H, Li X, et al
    Pretreatment arterial spin labeling combined with radiological depth of invasion predicts treatment outcome in nonmetastatic NPC.
    Radiother Oncol. 2025;205:110765.
    PubMed     Abstract available
    
    
    March 2025
27. ZENG Y, Hu Y, Wang L, Liao Z, et al
    Control of dental calculus Prevents severe Radiation-Induced oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Mar 27:110872. doi: 10.1016/j.radonc.2025.110872.
    PubMed     Abstract available
    
    
    
28. LI R, Wang X, Luo J, Bai H, et al
    Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.
    Radiother Oncol. 2025;207:110867.
    PubMed     Abstract available
    
    
    
29. YAN Y, Sun X, Chen Y, Sun Z, et al
    Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning.
    Radiother Oncol. 2025;207:110833.
    PubMed     Abstract available
    
    
    
30. KRISTENSEN MH, Nielsen SB, Alsner J, Sander Holm AI, et al
    A systematic review and proportional meta-analysis of image-based pattern of loco-regional failure analyses outcomes in head and neck squamous cell carcinoma.
    Radiother Oncol. 2025 Mar 13:110838. doi: 10.1016/j.radonc.2025.110838.
    PubMed     Abstract available
    
    
    
31. ZAYED S, Lang P, Read N, Correa RJM, et al
    Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.
    Radiother Oncol. 2025 Mar 5:110831. doi: 10.1016/j.radonc.2025.110831.
    PubMed     Abstract available
    
    
    February 2025
32. ANTUNES J, Young T, Pittock D, Jacobs P, et al
    Assessing multiple MRI sequences in deep learning-based synthetic CT generation for MR-only radiation therapy of head and neck cancers.
    Radiother Oncol. 2025 Feb 8:110782. doi: 10.1016/j.radonc.2025.110782.
    PubMed     Abstract available
    
    
    
33. VAN DER LAAN HP, Gawryszuk A, van der Schaaf A, Langendijk JA, et al
    Risk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study.
    Radiother Oncol. 2025;203:110698.
    PubMed     Abstract available
    
    
    January 2025
34. WAN D, Liu Q, Wei JS
    Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study".
    Radiother Oncol. 2025;205:110767.
    PubMed    
    
    
    
35. ZHAO C, Miao J
    Response to Dr. Dan Wan, Qing Liu, and Jia-Sha Wei's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiat
    Radiother Oncol. 2025 Jan 30:110768. doi: 10.1016/j.radonc.2025.110768.
    PubMed    
    
    
    
36. ZHONG J, Chen H, Chen X, Ma N, et al
    Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification.
    Radiother Oncol. 2025;205:110747.
    PubMed     Abstract available
    
    
    
37. NEH H, de Vette SPM, Stoffers RH, Zhou G, et al
    Normal tissue complication probability model predicting taste impairment in head and neck cancer patients: Evaluating the taste bud bearing tongue mucosa as a predictor.
    Radiother Oncol. 2025 Jan 28:110746. doi: 10.1016/j.radonc.2025.110746.
    PubMed     Abstract available
    
    
    
38. TORAIH E, Hussein M, Elshazli R, Abdelmaksoud A, et al
    Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis.
    Radiother Oncol. 2025;205:110706.
    PubMed     Abstract available
    
    
    
39. RAJENDRAN P, Yang Y, Niedermayr TR, Gensheimer M, et al
    Large language model-augmented learning for auto-delineation of treatment targets in head-and-neck cancer radiotherapy.
    Radiother Oncol. 2025;205:110740.
    PubMed     Abstract available
    
    
    
40. NERICH V, Falcoz A, Nadin L, Meurisse A, et al
    Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.
    Radiother Oncol. 2025;204:110726.
    PubMed     Abstract available
    
    
    
41. CHEN L, Li J, Li K, Hu J, et al
    Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy" [Radiother. Oncol. 190 (2024) 109985].
    Radiother Oncol. 2025;204:110719.
    PubMed    
    
    
    
42. LU T, Gao X, Yu Z, Liu L, et al
    Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience.
    Radiother Oncol. 2025;204:110713.
    PubMed     Abstract available
    
    
    
43. KAMPEL L, Feldstein S, Tsuriel S, Trejo LL, et al
    TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.
    Radiother Oncol. 2025;204:110714.
    PubMed     Abstract available
    
    
    
44. MENG X, Ju Z, Sakai M, Li Y, et al
    Normal tissue complication probability model for acute oral mucositis in patients with head and neck cancer undergoing carbon ion radiation therapy based on dosimetry, radiomics, and dosiomics.
    Radiother Oncol. 2025;204:110709.
    PubMed     Abstract available
    
    
    
45. ZHANG L, Zhang Z, Wang Y, Zhu Y, et al
    Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy.
    Radiother Oncol. 2025;204:110712.
    PubMed     Abstract available
    
    
    
46. LIU Y, Chen Z, Zhou Q, Shang X, et al
    A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose.
    Radiother Oncol. 2025;202:110593.
    PubMed     Abstract available
    
    
    December 2024
47. WINTER RM, Boeke S, Leibfarth S, Habrich J, et al
    Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer.
    Radiother Oncol. 2024;204:110702.
    PubMed     Abstract available
    
    
    
48. RUHLE A, Weymann M, Behrens M, Olbrich J, et al
    Predicting cisplatin tolerability in older adults with head and neck cancer - Insights for improved chemoradiation outcomes.
    Radiother Oncol. 2024 Dec 24:110697. doi: 10.1016/j.radonc.2024.110697.
    PubMed     Abstract available
    
    
    
49. GIRAUD P, Guihard S, Thureau S, Guilbert P, et al
    Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers.
    Radiother Oncol. 2024 Dec 21:110693. doi: 10.1016/j.radonc.2024.110693.
    PubMed     Abstract available
    
    
    
50. HE SQ, Liu GY, Yu YH, Wang L, et al
    Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
    Radiother Oncol. 2024 Dec 19:110687. doi: 10.1016/j.radonc.2024.110687.
    PubMed     Abstract available
    
    
    
51. ZHANG S, Yan L, Li R, Zhao Y, et al
    Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer.
    Radiother Oncol. 2024 Dec 19:110691. doi: 10.1016/j.radonc.2024.110691.
    PubMed     Abstract available
    
    
    
52. HUANG X, Lin K, Chen W, Zhang D, et al
    Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1alpha-HILPDA axis.
    Radiother Oncol. 2024 Dec 19:110686. doi: 10.1016/j.radonc.2024.110686.
    PubMed     Abstract available
    
    
    
53. KOCH A, Reinhardt P, Elicin O, Aebersold DM, et al
    Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review.
    Radiother Oncol. 2024 Dec 18:110689. doi: 10.1016/j.radonc.2024.110689.
    PubMed     Abstract available
    
    
    
54. LIANG JL, Wen YF, Huang YP, Guo J, et al
    A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study.
    Radiother Oncol. 2024;203:110660.
    PubMed     Abstract available
    
    
    
55. LI R, Zhao Y, Wu K, Li H, et al
    p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
    Radiother Oncol. 2024;201:110578.
    PubMed     Abstract available
    
    
    November 2024
56. MALLICK S
    Response to "Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma".
    Radiother Oncol. 2024;202:110656.
    PubMed    
    
    
    
57. SHI X, Hui B, Wang Y, Lu Y, et al
    Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma.
    Radiother Oncol. 2024 Nov 29:110655. doi: 10.1016/j.radonc.2024.110655.
    PubMed    
    
    
    
58. JIMENEZ-LABAIG P, Aymerich C, Rullan A, Cacicedo J, et al
    Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies.
    Radiother Oncol. 2024;202:110649.
    PubMed     Abstract available
    
    
    
59. WU CN, Wang JD, Chen WC, Lin CY, et al
    Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study.
    Radiother Oncol. 2024 Nov 23:110648. doi: 10.1016/j.radonc.2024.110648.
    PubMed     Abstract available
    
    
    
60. LIU M, Pang B, Chen S, Zeng Y, et al
    Deep learning-based multiple-CT optimization: An adaptive treatment planning approach to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2024;202:110650.
    PubMed     Abstract available
    
    
    
61. URSINO S, Malfatti G, Felice F, Bonomo P, et al
    Deglutition preservation after swallowing (Swoars)-sparing IMRT in head and neck cancers: Definitive results of A multicenter prospective study of the italian association of radiotherapy and clinical oncology (Airo).
    Radiother Oncol. 2024 Nov 22:110651. doi: 10.1016/j.radonc.2024.110651.
    PubMed     Abstract available
    
    
    
62. HUANG LW, Pan JW, Li B, Wu WX, et al
    Evaluation of radiation induced brain injury in nasopharyngeal carcinoma patients based on multi-parameter quantitative MRI: A prospective longitudinal study.
    Radiother Oncol. 2024 Nov 11:110621. doi: 10.1016/j.radonc.2024.110621.
    PubMed     Abstract available
    
    
    
63. ZHU MY, Wu HJ, Fang T, Zhang GS, et al
    Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.
    Radiother Oncol. 2024 Nov 11:110620. doi: 10.1016/j.radonc.2024.110620.
    PubMed     Abstract available
    
    
    
64. MALLICK S, Dagar A, Ghosh A, Aashita, et al
    Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
    Radiother Oncol. 2024 Nov 8:110611. doi: 10.1016/j.radonc.2024.110611.
    PubMed     Abstract available
    
    
    
65. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
    Radiother Oncol. 2024 Nov 8:110612. doi: 10.1016/j.radonc.2024.110612.
    PubMed     Abstract available
    
    
    
66. VAN BRUGGEN IG, van Dijk M, Brinkman-Akker MJ, Lofman F, et al
    Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study.
    Radiother Oncol. 2024;200:110522.
    PubMed     Abstract available
    
    
    
67. YANG WC, Koto M, Ikawa H, Imai R, et al
    Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma.
    Radiother Oncol. 2024;200:110511.
    PubMed     Abstract available
    
    
    
68. XU MH, Dou JP, Guo MH, Yi WQ, et al
    Risk factors for recurrent laryngeal nerve injury in microwave ablation of thyroid nodules: A multicenter study.
    Radiother Oncol. 2024;200:110516.
    PubMed     Abstract available
    
    
    
69. CHEN AM
    De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much...and what next?
    Radiother Oncol. 2024;200:110373.
    PubMed     Abstract available
    
    
    
70. CHEN B, Zhan Z, Xu Y, Yu S, et al
    Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.
    Radiother Oncol. 2024 Nov 1:110613. doi: 10.1016/j.radonc.2024.110613.
    PubMed     Abstract available
    
    
    October 2024
71. TATTENBERG S, Shin J, Hoehr C, Sung W, et al
    Correlation of dynamic blood dose with clinical outcomes in radiotherapy for head-and-neck cancer.
    Radiother Oncol. 2024 Oct 29:110603. doi: 10.1016/j.radonc.2024.110603.
    PubMed     Abstract available
    
    
    
72. GAITO S, Hwang E, Thwaites D, Ahern V, et al
    Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy.
    Radiother Oncol. 2024 Oct 26:110597. doi: 10.1016/j.radonc.2024.110597.
    PubMed     Abstract available
    
    
    
73. FELDMAN J, Pryanichnikov A, Shwartz D, Hillman Y, et al
    Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.
    Radiother Oncol. 2024;201:110572.
    PubMed     Abstract available
    
    
    
74. LIANG Z, Luo C, Li S, Zhu Y, et al
    Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect.
    Radiother Oncol. 2024 Oct 9:110571. doi: 10.1016/j.radonc.2024.110571.
    PubMed     Abstract available
    
    
    
75. PAN J, Qiu Z, Fu G, Liang J, et al
    Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk.
    Radiother Oncol. 2024;199:110420.
    PubMed     Abstract available
    
    
    September 2024
76. THIRUVENGADAM R, Kim SH, Thiruvengadam M
    Fructose 1,6-bisphosphate aldolase: A promising prognostic marker for oral cancer and its role in radiotherapy response.
    Radiother Oncol. 2024;200:110537.
    PubMed     Abstract available
    
    
    
77. DAVE J
    Concerns regarding the use of only phase 2 study to Justify palliative radiotherapy vs. Palliative chemo-radiotherapy in unresectable head and neck cancer.
    Radiother Oncol. 2024;200:110526.
    PubMed    
    
    
    
78. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
    Reducing the lateral dose penumbra in IMPT by incorporating transmission pencil beams.
    Radiother Oncol. 2024;198:110388.
    PubMed     Abstract available
    
    
    August 2024
79. YANG Y, Shao R, Cao X, Chen M, et al
    Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.
    Radiother Oncol. 2024;200:110517.
    PubMed     Abstract available
    
    
    
80. ZHU WY, Huang J, Lu ZQ, Yang S, et al
    Management of post-radiation carotid blowout syndrome in patients with head and neck cancer: A systematic review.
    Radiother Oncol. 2024;200:110502.
    PubMed     Abstract available
    
    
    
81. CHEN L, Wang H, Chen W, Li K, et al
    Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
    Radiother Oncol. 2024 Aug 25:110497. doi: 10.1016/j.radonc.2024.110497.
    PubMed     Abstract available
    
    
    
82. REINEMA FV, Hudson N, Adema GJ, Peeters WJM, et al
    MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.
    Radiother Oncol. 2024;200:110503.
    PubMed     Abstract available
    
    
    
83. BEUKEMA JC, Haveman JW, Langendijk JA, Oldehinkel E, et al
    Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.
    Radiother Oncol. 2024;200:110479.
    PubMed     Abstract available
    
    
    
84. TOPKAN E, Somay E, Selek U
    Comment on: Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
    Radiother Oncol. 2024;199:110467.
    PubMed    
    
    
    
85. MA B, Guo J, De Biase A, van Dijk LV, et al
    PET/CT based transformer model for multi-outcome prediction in oropharyngeal cancer.
    Radiother Oncol. 2024;197:110368.
    PubMed     Abstract available
    
    
    July 2024
86. SATO M, Hirose K
    A simple prediction model for the risk of boron neutron capture therapy-induced nausea and vomiting in head and neck cancer.
    Radiother Oncol. 2024;199:110464.
    PubMed     Abstract available
    
    
    
87. MENESES AG, Ferreira EB, Vieira LAC, Bontempo PSM, et al
    Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial.
    Radiother Oncol. 2024;199:110440.
    PubMed     Abstract available
    
    
    
88. XIE C, Yu X, Tan N, Zhang J, et al
    Combined deep learning and radiomics in pretreatment radiation esophagitis prediction for patients with esophageal cancer underwent volumetric modulated arc therapy.
    Radiother Oncol. 2024;199:110438.
    PubMed     Abstract available
    
    
    
89. ZUKAUSKAITE R, Kristensen MH, Eriksen JG, Johansen J, et al
    Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin.
    Radiother Oncol. 2024;196:110284.
    PubMed     Abstract available
    
    
    
90. CHIANG CL, Chan KSK, Li H, Ng WT, et al
    Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
    Radiother Oncol. 2024;196:110287.
    PubMed     Abstract available
    
    
    
91. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
    Response to letter to the editor by Somay et al., re: "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
    Radiother Oncol. 2024 Jul 1:110412. doi: 10.1016/j.radonc.2024.110412.
    PubMed    
    
    
    June 2024
92. NAVRAN A, Kayembe MT, Gouw ZAR, Vogel WV, et al
    FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection.
    Radiother Oncol. 2024;198:110407.
    PubMed     Abstract available
    
    
    
93. TOPKAN E, Somay E, Selek U
    Letter to the editor regarding "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
    Radiother Oncol. 2024 Jun 25:110411. doi: 10.1016/j.radonc.2024.110411.
    PubMed    
    
    
    
94. CANTERS R, van der Klugt K, Trier Taasti V, Buijsen J, et al
    Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion.
    Radiother Oncol. 2024 Jun 23:110409. doi: 10.1016/j.radonc.2024.110409.
    PubMed     Abstract available
    
    
    
95. SATO M, Hirose K
    Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation in Japan.
    Radiother Oncol. 2024 Jun 14:110382. doi: 10.1016/j.radonc.2024.110382.
    PubMed     Abstract available
    
    
    
96. MOORE-PALHARES D, Saifuddin M, Dasgupta A, Anzola Pena ML, et al
    Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial.
    Radiother Oncol. 2024;198:110380.
    PubMed     Abstract available
    
    
    
97. ZHOU H, Zhao Q, Huang W, Liang Z, et al
    A novel fully automatic segmentation and counting system for metastatic lymph nodes on multimodal magnetic resonance Imaging: Evaluation and prognostic implications in Nasopharyngeal carcinoma.
    Radiother Oncol. 2024 Jun 2:110367. doi: 10.1016/j.radonc.2024.110367.
    PubMed     Abstract available
    
    
    
98. LIU YC, Zhang X, Yang HN, Zhang L, et al
    Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution.
    Radiother Oncol. 2024;195:110225.
    PubMed     Abstract available
    
    
    May 2024
99. JOSE BESSO M, Bitto V, Koi L, Wijaya Hadiwikarta W, et al
    Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
    Radiother Oncol. 2024 May 30:110348. doi: 10.1016/j.radonc.2024.110348.
    PubMed     Abstract available
    
    
    
100. GEHIN W, Chastagner P, Mansuy L, Bernier-Chastagner V, et al
     Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart.
     Radiother Oncol. 2024 May 26:110346. doi: 10.1016/j.radonc.2024.110346.
     PubMed     Abstract available
     
     
     
101. SONG J, Yang X, Wu J, Wu Z, et al
     The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.
     Radiother Oncol. 2024 May 24:110340. doi: 10.1016/j.radonc.2024.110340.
     PubMed     Abstract available
     
     
     
102. ZHANG L, Jin S, Wang Y, Zhang Z, et al
     Predict nutrition-related adverse outcomes in head and neck cancer patients undergoing radiotherapy: A systematic review.
     Radiother Oncol. 2024 May 23:110339. doi: 10.1016/j.radonc.2024.110339.
     PubMed     Abstract available
     
     
     
103. NIELSEN CP, Lorenzen EL, Jensen K, Eriksen JG, et al
     Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines.
     Radiother Oncol. 2024;197:110337.
     PubMed    
     
     
     
104. BOREL C, Sun XS, Coutte A, Bera G, et al
     Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
     Radiother Oncol. 2024;197:110329.
     PubMed     Abstract available
     
     
     
105. ZHANG WW, Guo R
     Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".
     Radiother Oncol. 2024 May 11:110327. doi: 10.1016/j.radonc.2024.110327.
     PubMed    
     
     
     
106. ZHAN ZJ, Huang HY, Xiao YH, Zhao YP, et al
     Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.
     Radiother Oncol. 2024 May 10:110324. doi: 10.1016/j.radonc.2024.110324.
     PubMed     Abstract available
     
     
     
107. SHEN M, Lin X, Yang C, Zhou Z, et al
     Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
     Radiother Oncol. 2024 May 9:110323. doi: 10.1016/j.radonc.2024.110323.
     PubMed     Abstract available
     
     
     
108. SMITS HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, et al
     Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology.
     Radiother Oncol. 2024;194:110182.
     PubMed     Abstract available
     
     
     April 2024
109. XU L, Liu S, Yang Y, Shu L, et al
     LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.
     Radiother Oncol. 2024;196:110310.
     PubMed     Abstract available
     
     
     
110. LIU Y, Ma J, Zeng XY, Zuo ZC, et al
     Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
     Radiother Oncol. 2024;196:110311.
     PubMed     Abstract available
     
     
     
111. STARUCH M, Speth MM, Neyer P, Riesterer O, et al
     Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review.
     Radiother Oncol. 2024 Apr 20:110279. doi: 10.1016/j.radonc.2024.110279.
     PubMed     Abstract available
     
     
     
112. SELENGE BEDUK ESEN C, Nur Can G, Akkus Yildirim B
     Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".
     Radiother Oncol. 2024 Apr 20:110292. doi: 10.1016/j.radonc.2024.110292.
     PubMed    
     
     
     
113. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
     Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
     Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
     PubMed     Abstract available
     
     
     
114. ZHENG Z, Shen Y, Su J, Ji X, et al
     Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
     Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
     PubMed     Abstract available
     
     
     
115. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
     Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
     Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
     PubMed     Abstract available
     
     
     
116. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
     A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
     Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
     PubMed     Abstract available
     
     
     
117. SHUANG H, Feng J, Caineng C, Qifeng J, et al
     Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
     Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
     PubMed     Abstract available
     
     
     
118. CHOW JCH, Lee J, Lai MMP, Li S, et al
     Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
     Radiother Oncol. 2024;193:110143.
     PubMed     Abstract available
     
     
     March 2024
119. DONG J, Ng WT, Wong CHL, Li JS, et al
     Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
     Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
     PubMed     Abstract available
     
     
     
120. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
     Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
     Radiother Oncol. 2024;195:110231.
     PubMed     Abstract available
     
     
     
121. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
     Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
     Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
     PubMed     Abstract available
     
     
     
122. BOON CS, Ramkumar S, Boon IS
     Proton beam radiotherapy head and neck cancer study design and endpoints.
     Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
     PubMed    
     
     
     
123. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
     Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
     Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
     PubMed     Abstract available
     
     
     
124. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
     Neurological complications of modern radiotherapy for head and neck cancer.
     Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
     PubMed     Abstract available
     
     
     
125. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
     Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
     Radiother Oncol. 2024;192:110109.
     PubMed     Abstract available
     
     
     
126. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
     Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
     Radiother Oncol. 2024;194:110189.
     PubMed     Abstract available
     
     
     February 2024
127. POPULAIRE P, Defraene G, Haustermans K
     Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
     Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
     PubMed    
     
     
     
128. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
     Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
     Radiother Oncol. 2024;194:110180.
     PubMed     Abstract available
     
     
     November 2023
129. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
     Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
     Radiother Oncol. 2023;188:109889.
     PubMed     Abstract available
     
     
     October 2023
130. CHANG CL, Lin KC, Chen WM, Shia BC, et al
     Comparing the Oncologic Outcomes of Proton Therapy and Intensity-Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
     Radiother Oncol. 2023 Oct 28:109971. doi: 10.1016/j.radonc.2023.109971.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge.